OmniComm Systems, Inc.
Mobile technology extends electronic data capture to the point-of-clinical testing
Fort Lauderdale, FL, March 19, 2014 – OmniComm Systems, Inc. (OTC: OMCM), signed a five year agreement with Centre for Human Drug Research (CHDR), a clinical research center in The Netherlands, for Promasys mobile electronic data capture (EDC) technology. This agreement gives CHDR the ability to capture data right at the point-of-clinical testing utilizing the latest in mobile technology.
- CHDR uses Promasys technology to conduct more than thirty Phase I and IIa clinical studies per year across a full range of early stage clinical pharmacology research and sponsor based clinical studies.
- The Promasys iPad app meets the day-to-day demands of clinical research centers providing study staff the flexibility and freedom to enter clinical data at the point-of-clinical testing without sacrificing data quality or functionality.
- Promasys widespread adoption and utilization at CHDR is based on the application’s ability to rapidly and efficiently impact study build and setup. Promasys’ rapid clinical acceptance with research staff is in large part due to the intuitive user interface, high data quality, point and click features and elimination of programming.
- Promasys generated clinical data has been used by CHDR researchers to publish over 450 peer reviewed scientific papers.
- OmniComm Systems acquired Promasys BV in November 2013 adding a market leading EDC system for Investigator Initiated Studies to its product portfolio.
- Promasys is used by more than 35 research organizations, academic medical centers and hospitals, predominately in Asia and Europe, and in the USA.
- Promasys was developed in partnership with clinical research investigators and research staff to the meet the unique EDC demands required by Investigator Initiated Studies and academic researchers.
“We are very pleased to continue our longstanding relationship with the OmniComm Promasys product,” says Adam Cohen, M.D., Ph.D., professor of clinical pharmacology and CEO, CHDR. “CHDR performs perhaps the most complicated pharmacokinetic-dynamic studies in the field and our studies produce a data flow that would be unmanageable without this system. The change to the iPad product leads to immediate and considerable savings in staff costs that easily outweighs the acquisition cost. The smooth workflow from design of the database to the final publication is another feature we could not do without.”
For the first time, innovative mobile technology by Promasys delivers an EDC solution that enables research staff the flexibility to capture vital clinical information at the point-of-testing.
“Most commercially available EDC solutions are not designed to support the needs of investigators for investigator initiated trials and academic clinical research centers,” said Stephen Johnson, president, OmniComm Systems. “The Promasys technology is the first commercially viable solution designed with the needs of the academic research environment in mind – built by investigators for investigators.”
Supporting InformationOmniComm Systems, Inc. Acquires Promasys BV
About OmniComm Systems
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm and TrialMaster are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.